Urinary KIM-1 and NAG in NSAID Users with Preserved Serum Creatinine: An Exploratory Cross-sectional Study from Iraq
DOI:
https://doi.org/10.46966/msjar.v7i3.480Keywords:
NSAID-associated nephrotoxicity; kidney injury molecule-1; N-acetyl-β-D-glucosaminidase; tubular injury; biomarkers; exploratory studyAbstract
Background: NSAIDs can induce renal tubular damage which is not detected by standard serum markers. The aim of this study was to investigate urinary KIM-1 and NAG in the NSAID-using patients having normal and renal failure. Aim: To assess urinary KIM-1 and NAG levels in NSAID users with normal and moderately reduced renal function and explore their relationship with conventional serum markers. Methods: A cross sectional study was conducted in Thi-Qar teaching hospital from January to April 2025. There were 25 controls, 30 NSAID users with normal serum creatinine and eGFR >60 mL/min/1.73 m², and 25 NSAID users with moderate reduction of eGFR. The levels of serum creatinine, urea, eGFR, urinary KIM-1 and NAG were measured. Results: Urinary KIM-1 and NAG were significantly higher in NSAID users with normal serum markers than in controls (KIM-1: 3.12±0.93 vs 0.40±0.15 ng/mL; NAG: 8.88±2.52 vs 2.47±0.64 U/g Cr; both p<0.001). There were higher levels in the reduced-EGFR group. In the normal-marker group, there was not a significant association between urinary biomarkers and serum creatinine. Conclusion: Urinary KIM-1 and NAG levels were high in some of the NSAID users with normal serum creatinine, indicating possible tubular damage. These results are preliminary and cannot be used to draw conclusions about the diagnosis superiority or the use of routine biomarker monitoring, however, because of the cross-sectional design, the absence of baseline measurements and possible confounding by age, BMI and duration of NSAID use.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2027 Kareema Allawi Dakhil, Khansaa A. Hussein

This work is licensed under a Creative Commons Attribution 4.0 International License.
In submitting the manuscript to the Medical Science Journal for Advance Research, the authors certify that:
- They are authorized by their co-authors to enter into these arrangements.
- The work described has not been formally published before, except in the form of an abstract or as part of a published lecture, review, thesis, or overlay journal.
- That it is not under consideration for publication elsewhere,
- The publication has been approved by the author(s) and by responsible authorities – tacitly or explicitly – of the institutes where the work has been carried out.
- They secure the right to reproduce any material that has already been published or copyrighted elsewhere.
- They agree to the following license and copyright agreement.
License and Copyright Agreement
Authors who publish with Medical Science Journal for Advance Research agree to the following terms:
- Authors retain copyright and grant the Medical Science Journal for Advance Research right of first publication with the work simultaneously licensed under Creative Commons Attribution License (CC BY 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the Medical Science Journal for Advance Research published version of the work (e.g., post it to an institutional repository or edit it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.


















